1015 Capital Partners’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-4
Closed -$58 – 491
2026
Q2
$58 Sell
4
-6
-60% -$106 ﹤0.01% 608
2026
Q1
$190 Buy
10
+9
+900% +$146 ﹤0.01% 576
2025
Q4
$17 Buy
+1
New +$19 ﹤0.01% 630

Other funds holding SMMT

1015 Capital Partners's SMMT Position: Q3 2026 in Review

1015 Capital Partners sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 4 shares — an estimated $58 sold.

1015 Capital Partners first reported a position in SMMT in Q4 2025 and held it in 3 quarters. The position peaked at $190 in Q1 2026. 297 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • 1015 Capital Partners reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • 1015 Capital Partners sold 4 Summit Therapeutics shares in Q3 2026, an estimated $58.
  • 1015 Capital Partners first reported a position in Summit Therapeutics in Q4 2025 and held it in 3 quarters.
  • 1015 Capital Partners's Summit Therapeutics position peaked at $190 in Q1 2026.
  • 297 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on 1015 Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.